Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (NOH303)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chelsea Therapeutics
ClinicalTrials.gov Identifier:
NCT00738062
First received: August 19, 2008
Last updated: April 22, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.


Condition Intervention Phase
Neurogenic Orthostatic Hypotension
Non-Diabetic Autonomic Neuropathy
Multiple System Atrophy
Dopamine Beta Hydroxylase Deficiency
Drug: Droxidopa
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Resource links provided by NLM:


Further study details as provided by Chelsea Therapeutics:

Primary Outcome Measures:
  • Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.

    In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization.



Secondary Outcome Measures:
  • Change in Orthostatic Hypotension Daily Activities (OHDAS) Score [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.

    Change: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug).


  • Change in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.

    Change: score at end of randomization minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug).


  • Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug). All patients are on open-label droxidopa for 3 months prior to randomization to either continued droxidopa or to placebo.

  • Patient Reported Clinical Global Impression - Severity [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;

    • Normal-Borderline OH (CGI-S 1-2),
    • Mild-Moderate OH (CGI-S 3-4),
    • Marked OH-Most Ill with OH (CGI-S 5-7). .

  • Clinician Recorded Clinical Global Impression - Severity [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;

    • Normal-Borderline OH (CGI-S 1-2),
    • Mild-Moderate OH (CGI-S 3-4),
    • Marked OH-Most Ill with OH (CGI-S 5-7).

  • Patient Reported Clinical Global Impression - Improvement [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.

    Patients will be grouped according change in disease as follows;

    • Very Much Improved to Slightly Improved (CGI-I 1-3),
    • No Change (CGI-I 4),
    • Slightly Worse to Very Much Worse (CGI-I 5-7).

  • Clinician Rated Clinical Global Impressions - Improvement [ Time Frame: 14 days ] [ Designated as safety issue: No ]

    The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.

    Patients will be grouped according change in disease as follows;

    • Very Much Improved to Slightly Improved (CGI-I 1-3),
    • No Change (CGI-I 4),
    • Slightly Worse to Very Much Worse (CGI-I 5-7).


Enrollment: 103
Study Start Date: January 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Droxidopa
Study medication
Drug: Droxidopa
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Other Name: Droxidopa
Placebo Comparator: Placebo
Placebo
Drug: Placebo
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Other Name: Inactive drug (to look like Droxidopa)

Detailed Description:

Systolic blood pressure is transiently and minimally decreased in healthy individuals upon standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness and blurred or impaired vision, among other symptoms.

The autonomic nervous system has a central role in the regulation of blood pressure. Primary Autonomic Failure is manifested in a variety of syndromes. Orthostatic hypotension is a usual presenting symptom. Primary Autonomic Failure may be the primary diagnosis, and classifications include pure autonomic failure (PAF), also called idiopathic orthostatic hypotension (Bradbury-Eggleston syndrome) autonomic failure with multiple system atrophy (Shy-Drager syndrome) and also Parkinson's disease. Regardless of the primary condition, autonomic dysfunction underlies orthostatic hypotension.

Orthostatic hypotension may be a severely disabling condition which can seriously interfere with the quality of life of afflicted subjects. Currently available therapeutic options provide some symptomatic relief in a subset of subjects, but are relatively ineffective and are often accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone, methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the pharmacological interventions that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of these currently available therapeutic options, and the incapacitating nature and often progressive downhill course of disease, point to the need for an improved therapeutic alternative.

The current withdrawal design study will measure the efficacy of droxidopa on symptoms of neurogenic orthostatic hypotension in patients randomized to continued droxidopa treatment versus placebo, following 14 days of double-blind treatment.

Droxidopa

Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible for inclusion, each patient must fulfill the following criteria:

  • Participated in Droxidopa Protocol 302;
  • Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.

Exclusion Criteria:

Patients are not eligible for this study if they fulfill one or more of the following criteria:

  • Currently taking ephedrine or midodrine;
  • Patients taking ephedrine or midodrine must stop taking these drugs at least 2 days prior to their study entry visit (Visit 1).
  • Currently taking anti-hypertensive medication;

    * The use of short-acting anti-hypertensive medications at bedtime is permitted.

  • Currently taking tri-cyclic antidepressant medication or other norepinephrine re-uptake inhibitors;
  • Have changed dose, frequency and or type of prescribed medication, within two weeks of study start (excluding ephedrine and midodrine);
  • History of more than moderate alcohol consumption;
  • History of known or suspected drug or substance abuse;
  • Women of childbearing potential who are not using a medically accepted contraception;

    • Reproductive potential:
    • Female subjects should be either post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) who are using or agree to use acceptable methods of contraception.
    • Acceptable contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
    • For WOCP a urine pregnancy test must be conducted at each study visit.
    • WOCP must be advised to use acceptable contraceptives throughout the study period and for 30 days after the last dose of investigational product.
    • If hormonal contraceptives are used they should be taken according to the package insert.
    • WOCP who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for 30 days after the last dose of investigational product.
  • Sexually active males whose partner is a WOCP and who do not agree to use condoms for the duration of the study and for 30 days after the last dose;
  • Women who are pregnant or breast feeding;
  • Known or suspected hypersensitivity to the study medication or any of its ingredients;
  • Pre-existing sustained severe hypertension (BP 180/110 mmHg in the sitting position);
  • Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;
  • Any other significant systemic, hepatic, cardiac or renal illness;
  • Diabetes mellitus or insipidus;
  • Have a history of closed angle glaucoma;
  • Have a known or suspected malignancy;
  • Have a serum creatinine level > 130 umol/L;
  • Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;
  • In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing;
  • In the investigator's opinion, are unable to adequately co-operate because of individual or family situation;
  • In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia;
  • Are not able or willing to comply with the study requirements for the duration of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00738062

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
United States, Arizona
Dedicated Clinical Research
Litchfield Park, Arizona, United States, 85340
Xenoscience Inc.
Phoenix, Arizona, United States, 85004
Sun Health Research Institute
Sun City, Arizona, United States, 85351
United States, California
The Parkinson's and Movement Disorders Institute
Fountain Valley, California, United States, 92708
Pacific Neuroscience Medical Group
Oxnard, California, United States, 93030
The Parkinson's Institute
Sunnyvale, California, United States, 94085
United States, Colorado
Electrophysiology Associates
Colorado Springs, Colorado, United States, 80910
United States, Florida
Parkinson's Disease & Movment Disorder Center
Boca Raton, Florida, United States, 33486
Southeastern Integrated Medical
Gainesville, Florida, United States, 32607
Mayo Jacksonville Florida Department of Neurology
Jacksonville, Florida, United States, 32224
University of Miami Miller School of Medicine
Miami, Florida, United States, 33136
University of South Florida
Tampa, Florida, United States, 33606
United States, Georgia
Medical Associates of North Georgia
Canton, Georgia, United States, 30114
United States, Illinois
Saint Mary of Nazareth Hospital Center
Chicago, Illinois, United States, 60622
North Chicago VA Medical Center
North Chicago, Illinois, United States, 60064
United States, Indiana
Indiana Medical Research
Elkhart, Indiana, United States, 46514
JWM Neurology
Indianapolis, Indiana, United States, 46237
United States, Kansas
Kansas City Bone and Joint, PA
Overland Park, Kansas, United States, 66211
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Maryland
University of Maryland Hospital
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
University of Massachusetts Worcester
Worcester, Massachusetts, United States, 01655
United States, Michigan
Henry Ford Health System
Southfield, Michigan, United States, 48034
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University Medical Center
St. Louis, Missouri, United States, 63110
United States, New Jersey
New Jersey Neuroscience Institute
Edison, New Jersey, United States, 08818
United States, New York
Kingston Neurological Associates, PC
Kingston, New York, United States, 12401
Columbia University Neurological institute of NY
New York, New York, United States, 10032
NYU Medical Center
New York City, New York, United States, 10016
University of Rochester
Rochester, New York, United States, 14618
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Wake Forest University
Winston Salem, North Carolina, United States, 27157
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Cleveland Clinic
Cleveland, Ohio, United States, 44195
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
United States, Oklahoma
COR Clinical Research, LLC
Oklahoma City, Oklahoma, United States, 73103
United States, Oregon
The Oregon Clinic
Portland, Oregon, United States, 97213
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37212
United States, Texas
Jacinto Medical Group, PA
Baytown, Texas, United States, 77521
UT Southwestern Medical Center
Dallas, Texas, United States, 75390-9036
Scott & White Healthcare - Round Rock
Round Rock, Texas, United States, 78665
Scott & White Memorial Hospital & Clinic
Temple, Texas, United States, 76508
East Texas Medical Center - Neurological Institute Movment Disorders Center
Tyler, Texas, United States, 75701
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 3004
Australia
Austin Hospital
Heidelburg, Australia, 3084
Canada, Ontario
McMaster University
Hamilton, Ontario, Canada, L8L2X2
Centre for Movement Disorders
Markham, Ontario, Canada, L6B1C9
Parkinson's & Neurodegenerative Disorders Clinic
Ottawa, Ontario, Canada, K1G4G3
Canada, Quebec
SMBD Jewish General Hospital - Department of Neurology
Montreal, Quebec, Canada, H3T 1E2
Canada
Quebec Memory and Motor Skills Disorders Clinic
Quebec, Canada, G1R 3X5
New Zealand
Auckland Hospital
Grafton Auckland, Private Bag, New Zealand
Van der Veer Institute for Parkinson's Disease and Movement Disorders
Christchurch, New Zealand
Sponsors and Collaborators
Chelsea Therapeutics
Investigators
Principal Investigator: Horacio Kaufmann Kaufmann, MD NYU School of Medicine
Principal Investigator: Christopher J. Mathias, MD Imperial School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Chelsea Therapeutics
ClinicalTrials.gov Identifier: NCT00738062     History of Changes
Other Study ID Numbers: Droxidopa NOH303
Study First Received: August 19, 2008
Results First Received: March 18, 2014
Last Updated: April 22, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Chelsea Therapeutics:
NOH
Neurogenic Orthostatic Hypotension
Orthostatic hypotension
PAF
Pure Autonomic Failure
MSA
Multiple System Atrophy
Neuropathy
Autonomic Failure
Parkinson
Dopamine Deficiency
Dopamine
Droxidopa

Additional relevant MeSH terms:
Atrophy
Autonomic Nervous System Diseases
Hypotension
Hypotension, Orthostatic
Multiple System Atrophy
Nervous System Diseases
Shy-Drager Syndrome
Basal Ganglia Diseases
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Orthostatic Intolerance
Pathological Conditions, Anatomical
Primary Dysautonomias
Vascular Diseases
Droxidopa
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014